** Shares of drug developer GH Research GHRS.O rise 90% to $20.14 premarket
** Co's therapy for treatment-resistant depression meets main goal of mid-stage trial by reducing the severity of the disease as measured on a widely used scale
** GHRS says 57.5% of patients on the therapy, GH001, had less severe disease at 8 days
** GH001 also meets all secondary goals of the trials, GHRS adds
** GHRS rose 20.7% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.